anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Keratoconus is a common disease that affects the cornea in both genders in all ethnic groups and that can manifest unilaterally or bilaterally in patients. Keratoconus due to a degenerative disease, its progression can be fast in various situations, affecting 1 in every 2,000 people, what results in severe structural changes of the cornea, which reduces its thickness and modify its normal curvature to a more conical shape. Keratoconus arises in adolescence and lasts for thirty to forty years of age, where it stabilizes and it is considered a major cause of corneal transplantation. Factors such as atopy, overuse of contact lenses and the act of rubbing the eyes are also related to the disease. The clinical picture consists of a lot of varied symptoms and it depends on the stage of disease progression. Currently it is known that genetic and environmental factors are involved in the desease emergence. Recently several genetic studies have aimed to identify mutations in genes which are directly linked to Keratoconus, such as VSX1, SOD1 and TIMP3 genes. However, despite the efforts directed towards the understanding of the genetic aspects of this disease, involving many genes, there are still many questions about the role of these genes in Keratoconus etiology. Thus, the present study aims to identify the presence of mutations in VSX1, SOD1 and TIMP3 genes, which are considered important candidates for the origin and development of this eye anomaly, through the analysis of their nucleotide sequences in corneal tissue and peripheral blood in Keratoconus patients, in their unilateral and bilateral forms. The results will allow to compare the presented mutations in different analysed tissues for unilateral and bilateral forms of Keratoconus and also compare them with the same tissues in healthy patients, in an attempt to establish what the likely inherited and/or acquired genetic mutations are causing this condition. Thus providing genetic data, still unpublished in Brazilian populations, which may offer subsidies for the characterization of the mutation dynamics and their patterns, on the origin and development of Keratoconus. Also will be evaluated the tomographic index as corneal curvature, thinnest point, corneal high order aberrations, posterior and anterior elevation, corneal densitometry, corneal volume. The idea is focused on that suspicious cornea that has the fellow eye with unequivocal keratoconus.
At two study sites, we will randomly assign participants to the VTC/in-person group or CBT group using a ratio of 2:1 to assign participants to the VTC/in-person or CBT training modalities. We anticipate 84 participants (42 per site) will be assigned to the CBT modality and 168 (84 per site) will be assigned to the VTC/in-person modality.
Glucocorticoids (GCs) have been used in the treatment of sepsis because of their potent anti-inflammatory effects. However, their clinical efficacy against sepsis remains controversial because of glucocorticoid receptor (GR) downregulation and side effects. Herein, we designed and synthesized 30 ocotillol derivatives and evaluated their anti-inflammatory activities. Ocotillol 24(R/S) differential isomers were stereoselective in their pharmacological action. Specifically, 24(S) derivatives had better anti-inflammatory activity than their corresponding 24(R) derivatives. Compound 20 most effectively inhibited NO release (85.97% reduction), and it exerted dose-dependent inhibitory effects on interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) levels. Mechanistic studies revealed that compound 20 reduces the degradation of GR mRNA and GR protein. Meanwhile, compound 20 inhibited the activation of nuclear factor-κB (NF-κB) signaling, thereby inhibiting the nuclear translocation of p65 and attenuating the inflammatory response. In vivo studies revealed that compound 20 attenuated hepatic, pulmonary, and renal pathology damage in mice with sepsis and suppressed the production of inflammatory mediators. These results indicated that compound 20 is a promising lead compound for designing and developing anti-sepsis drugs.
White blood cells (WBCs) are robust defenders during antigenic challenges and prime immune cell functioning indicators. High-purity WBC separation is vital for various clinical assays and disease diagnosis. Red blood cells (RBCs) are a major hindrance in WBC separation, constituting 1000 times the WBC population. The study showcases a low-cost micropump integrated microfluidic platform to provide highly purified WBCs for point-of-care testing. An integrated user-friendly microfluidic platform was designed to separate WBCs from finger-prick blood (⁓5 μL), employing an inertial focusing technique. We achieved an efficient WBC separation with 86% WBC purity and 99.99% RBC removal rate in less than 1 min. In addition, the microdevice allows lab-on-chip colorimetric evaluation of chronic granulomatous disease (CGD), a rare genetic disorder affecting globally. The assay duration, straight from separation to disease detection, requires only 20 min. Hence, the proposed microfluidic platform can further be implemented to streamline various clinical procedures involving WBCs in healthcare industries.
This clinical trial is designed as a pilot, signal-finding study to demonstrate the feasibility of detecting ctDNA at baseline and after 4 weeks of treatment (primary endpoint), as well as correlating with disease status as per radiographic response (RR; secondary endpoint). In addition, the investigators will generate preliminary data for activity of plixorafenib co-administered with cobicistat in this heavily-pretreated population. Patients with measurable (by Response Assessment in Neuro-Oncology (RANO 2.0)), recurrent BRAF-V600E mutant glioma will be screened and consented for the study prior to surgery. Patients will undergo pre-operative MRI and clinically-indicated resection or biopsy (specific approach as per treating neurosurgeon) for confirmation of progression and characterization of potential acquired resistance alterations. All patients will have a ventricular reservoir placed at time of surgery with CSF and plasma sampling. Patients will start the study drug (plixorafenib 900mg daily co-administered with cobicistat 150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles. MRI will be performed post-operatively (between proof of delivery (POD#0) and start of study drug) for evaluation of measurable disease, after Cycle 1, then every 2 cycles. Blood and CSF samples will be obtained on day of surgery, at baseline, pre-C2, then with each MRI. A total of 12 evaluable patients will be enrolled. Patients who do not start drug will be replaced, up to a total of 15 patients.
The invention discloses an application of LINC01272 in preparing a tumor detection reagent and/or a therapeutic drug, wherein the sequence of LINC01272 is shown as SEQ ID No: 1 is shown. The invention provides a tumor detection kit, which comprises a reagent for detecting the expression level of LINC 01272; a tumor detection chip comprises a solid phase carrier and a probe fixed on the solid phase carrier, wherein the probe comprises a nucleotide sequence complementary with SEQ ID NO. 1. The invention also provides a medicament for treating tumors, comprising an inhibitor of LINC 01272. LINC01272 is up-regulated in cancer cells, and LINC01272 is used for developing a tumor detection kit or chip, and can judge whether the detected tissue is malignant tissue. The inhibition of the expression of the LINC01272 can effectively inhibit the proliferation and invasion of cancer cells, and the application of the LINC01272 expression inhibitor can treat tumors.
A medical image analysis method applying machine learning and system thereof are provided. The medical image analysis system includes a cloud server and an electronic device. The cloud server stores a deep learning module and an artificial intelligence model. The medical image analysis method includes the following steps. Correction data is inputted to the deep learning module so that the deep learning module corrects the artificial intelligence model according to the correction data to generate a corrected artificial intelligence model. Furthermore, medical image data is inputted to the electronic device, and the electronic device provides the medical image data to the cloud server to analyze the medical image data through the corrected artificial intelligence model and generates analysis result data.
The invention discloses a method for homogeneously preparing hydroxypropyl modified chitin with a low degree of deacetylation. The technical scheme is as follows: the method comprises the following steps: firstly, adding chitin into a mixed aqueous solution of a soluble alkali and urea to prepare a homogeneous chitin solution; then, adding a hydroxypropylatng reagent or an aqueous solution thereof to stir and react; and posttreating and drying to obtain the hydroxypropyl modified chitin with the low degree of deacetylation. The method disclosed by the invention is simple in preparation process, high in yield and mild in reaction condition, and uniform and easily control the degree of substitution of the product is uniform and easily controlled. Chitin is substantially not degraded and the degree of deaeetylation of chitin is reduced, thereby facilitating industrialized production on a large scale. The hydroxypropyl modified chitin with the low degree of deacetylation has temperature sensitivity and can be used as an injectable hydrogel and a medicine carrier material. As the chitin is cheap and biodegradable, the chitin can be widely applied to other medicine heat-care and food processing fields and the like.
Exosomes are nanovesicles 30-150 nm in diameter released extracellularly. Those isolated from human body fluids reflect the characteristics of their cells or tissues of origin. Exosomes carry extensive biological information from their parent cells and have significant potential as biomarkers for disease diagnosis and prognosis. However, there are limited studies utilizing exosomes in postmortem diagnostics. In this study, we extended our initial research which identified the presence and established detection methodologies for exosomes in postmortem fluids. We analyzed exosomal miRNA extracted from plasma and pericardial fluid samples of a control group (n = 13) and subjects with acute myocardial infarction (AMI; n = 24). We employed next-generation sequencing (NGS) to investigate whether this miRNA could serve as biomarkers for coronary atherosclerosis leading to acute myocardial infarction. Our analysis revealed 29 miRNAs that were differentially expressed in the AMI group compared to the control group. Among these, five miRNAs exhibited more than a twofold increase in expression across all samples from the AMI group. Specifically, miR-486-5p levels were significantly elevated in patients with high-grade (type VI or above) atherosclerotic plaques, as per the American Heart Association criteria, highlighting its potential as a predictive biomarker for coronary atherosclerosis progression. Our results indicate that postmortem-derived exosomal microRNAs can serve as potential biomarkers for various human diseases, including cardiovascular disorders. This finding has profound implications for forensic diagnostics, a field critically lacking diagnostic markers.
Background and Objectives: This study aimed to examine the relationship between cardiometabolic risk factors and atrial fibrillation (AF) and the simultaneous presence of AF and metabolic syndrome (MetS) in the Pakistani population. Materials and Methods: A total of 690 subjects were enrolled (n = 230 patients with AF, n = 230 patients with AF and MetS, and n = 230 controls). The associations between cardiometabolic parameters and AF with and without MetS were analyzed by univariable and multivariable binary regression analyses. Results: Body mass index (BMI), fasting blood glucose (FBG), and triglycerides (TG) were independently positively correlated, but the glomerular filtration rate (GFR) and sodium were independently negatively correlated with AF. An increase in BMI, FBG, and TG levels by one unit measure increased the probability by 55.1%, 20.6%, and 1.3%, respectively, for the AF occurrence. A decrease in GFR and sodium levels increased the probability by 4.3% and 33.6%, respectively, for the AF occurrence. On the other hand, uric acid was independently negatively correlated, whereas sodium was independently positively correlated, with MetS and AF. A decrease in uric acid levels and an increase in sodium levels by 1 unit measure increased the probability for MetS and AF by 23.2% and 7.5%, respectively. Conclusions: Cost-effective and routinely measured parameters, i.e., BMI, FBG TG, GFR, and sodium levels, can be reliable indicators of AF, whereas serum uric acid and sodium levels are independently associated with AF and MetS in the Pakistani population. Timely recognition and the control of modifiable cardiometabolic risk factors are of great significance in the prevention of AF development.
Liver transplant oncology (TO) represents an area of increasing clinical and scientific interest including a heterogeneous group of clinical-pathological settings. Immunosuppressive management after LT is a key factor relevantly impacting result. However, disease-related guidance is still lacking, and many open questions remain in the field. Based on such a substantial lack of solid evidences, the Italian Board of Experts in Liver Transplantation (I-BELT) (a working group including representatives of all national transplant centers), unprecedently promoted a methodologically sound consensus conference on the topic, based on the GRADE approach. The group final recommendations are herein presented and commented. The 18 PICOs and Statements and their levels of evidence and grades of recommendation are reported and grouped into seven areas: (1) risk stratification by histopathological and bio-molecular parameters and role of mTORi post-LT; (2) steroids and HCC recurrence; (3) management of immunosuppression when HCC recurs after LT; (4) mTORi monotherapy; (5) machine perfusion and HCC recurrence after LT; (6) physiopathology of tumor-infiltrating lymphocytes and immunosuppression, the role of inflammation; (7) immunotherapy in liver transplanted patients. The interest in mammalian targets of rapamycin inhibitors (mTORi), for steroid avoidance and the need for a reduction to CNI exposure emerged from the consensus process. A selected list of unmet needs prompting further investigations have also been developed. The so far heterogeneous and granular approach to immunosuppression in oncologic patients deserves greater efforts for a more standardized therapeutic response to the different clinical scenarios. This consensus process makes a first unprecedented step in this direction, to be developed on a larger scale.
Participants will receive daily weight loss medication, Contrave, at a dose of 360 mg (Naltrexone HCl 32mg, Bupropion HCl 360mg). The dose will be titrated: 8 mg/90 mg on Week 1, 16 mg/180 mg on Week 2, 24 mg/270 mg on Week 3 and 32 mg/360 mg on Week 4. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone.
Oral branched-chain amino acid (BCAA) is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
Women continue to comprise a growing proportion of the new HIV infections around the world. A growing body of data suggests that a safe and effective topical microbicide will be a real option of prevention for women in the future. The purpose of this study is to assess the safety and acceptability of 3% SPL7013 Gel when administered intravaginally, twice daily for 14 consecutive days in healthy, sexually-active, HIV-uninfected women.

The expected duration of this study for each participant is 21 days. Study participants will be randomly assigned to one of two arms. Participants in Arm 1 will apply 3.5 g of SPL7013 gel intravaginally twice daily for 14 consecutive days. Participants in Arm 2 will apply a placebo gel intravaginally twice daily for 14 consecutive days. Starpharma produces SPL7013 gel (VivaGel) and will provide it for this study.

After enrollment, participants will attend three study visits. These visits will occur on Days 7, 14, and 21. A follow-up safety visit will occur if necessary. Medical and menstrual history, targeted physical exam, urine and blood collection, cervical swabs, and vaginal smears will occur at all visits. A colposcopy will occur at least once. On Day 2, participants will take part in a phone assessment.
PROBLEM TO BE SOLVED: To obtain a permanent waving composition excellent in foaming power and wetting property or permeability and having good compatibility with skin by using a specific surfactant. SOLUTION: This permanent waving composition contains an alkylamide ether carboxylic acid of the formula [R is a 8-18C alkyl; (n) is 1-10] or its water-soluble salt as a main surfactant. A compound of the formula wherein R is an 12-14C alkyl and (n) is 2 5 is preferably used as the compound of the formula. An alkali metal salt, especially sodium salt is preferably used as the water soluble salt of the compound of the formula. The compound of the formula can be blended with either one or both of a reducing agent composition and a neutralizing agent composition. A blend amount of the compound of the formula to the reducing agent composition is preferably 0.1-5wt.%, especially preferably about 0.25-2.5wt.% based on total composition. A blend amount of the compound of the formula to the neutralizing agent composition is preferably 0.25-10wt.%, especially preferably 0.5-5wt.%, further preferably 1-2.5wt.%. Other surfactant, especially anionic surfactant can be blended into the system.
A non-specific substantially non-toxic immunogenic agent adapted for use in stimulating non-specific immunity is obtained by incompletely acylating under substantially anhydrous conditions a pyrogenic lipopolysaccharide endotoxin extracted from a bacterial endotoxin-producing source microorganism, cooling the reaction-mixture to form a precipitate, separating the precipitate from the residual liquid, treating the precipitate with a pyrogen-free aqueous medium to form a fine suspension and precipitate, separating the precipitate, washing the precipitate with pyrogen-free water and recovering the immunogenic agent from the washed precipitate.  Acylation may be carried out at 80-120 DEG C. by means of acetic anhydride or benzoyl chloride.  A preferred endotoxin is a trichloroacetic acid extract of Salmonella typhosa.  Other microorganisms may be used e.g. E. coli, Pseudomonas aeruginosa, Serratia marscens, Brucella abortus, Shigella dysenteriae, Hemophilus pertussis, S. aureus and M. tuberculosis.  The immunogenic agent may be admixed with sulphonamides and antibiotics, e.g. penicillin and streptomycin.
Dendrimer conjugates are presented, which are formed between a dendrimer and a protein solubilising substance. Such dendrimer conjugates are effective in the treatment of protein aggregate-related diseases (e.g. prion-related diseases). The protein solubilising substance and the dendrimer together show a protein aggregate solubilising effect higher than a physical mixture of the dendrimer and the protein solubilising substance (i.e. a synergistic effect). Such dendrimer conjugates are useful in the treatment or prevention of protein aggregate-relates diseases, in disinfection/decontamination processes and in classifying or identifying protein aggregates. The synthesis of such dendrimer conjugates from readily-available starting materials is described.
To construct a prediction model of olfactory dysfunction after transnasal sellar pituitary tumor resection based on machine learning algorithms. A cross-sectional study was conducted. From January to December 2022, 158 patients underwent transnasal sellar pituitary tumor resection in three tertiary hospitals in Sichuan Province were selected as the research objects. The olfactory status was evaluated one week after surgery. They were randomly divided into a training set and a test set according to the ratio of 8:2. The training set was used to construct the prediction model, and the test set was used to evaluate the effect of the model. Based on different machine learning algorithms, BP neural network, logistic regression, decision tree, support vector machine, random forest, LightGBM, XGBoost, and AdaBoost were established to construct olfactory dysfunction risk prediction models. The accuracy, precision, recall, F1 score, and area under the ROC curve (AUC) were used to evaluate the model's prediction performance, the optimal prediction model algorithm was selected, and the model was verified in the test set of patients. Of the 158 patients, 116 (73.42%) had postoperative olfactory dysfunction. After missing value processing and feature screening, an essential order of influencing factors of olfactory dysfunction was obtained. Among them, the duration of operation, gender, type of pituitary tumor, pituitary tumor apoplexy, nasal adhesion, age, cerebrospinal fluid leakage, blood scar formation, and smoking history became the risk factors of olfactory dysfunction, which were the key indicators of the construction of the model. Among them, the random forest model had the highest AUC of 0.846, and the accuracy, precision, recall, and F1 score were 0.750, 0.870, 0.947, and 0.833, respectively. Compared with the BP neural network, logistic regression, decision tree, support vector machine, LightGBM, XGBoost, and AdaBoost, the random forest model has more advantages in predicting olfactory dysfunction in patients after transnasal sellar pituitary tumor resection, which is helpful for early identification and intervention of high-risk clinical population, and has good clinical application prospects.
A modified "3+3" dose-escalation design is used, with BGT007H cells administered at five progressively increasing dose levels for treatment evaluation. The dose levels are (3.0×10\^7, 1.0×10\^8, 2.0×10\^8, 3.0×10\^8, 4.0×10\^8) BGT007H cells.
The present invention relates to a ligand binding to MSRV-ENV, comprising each of the complementary-determining regions (CDRs): CDR1 of a light chain variable region (VL) set forth in SEQ ID No. 1, CDR2 VL set forth in SEQ ID No. 2, CDR3 VL set forth in SEQ ID No. 3, CDR4 of a heavy chain variable region (VH) set forth in SEQ ID No. 4, CDR5 VH set forth in SEQ ID No. 5 and CDR6 VH set forth in SEQ ID No. 6. Said ligand may be used in treating MSRV-associated diseases. Furthermore, the invention relates to variants of said ligand, ScFV, Fab fragments, an antibody comprising the ligands by the invention, a method of producing the same, a pharmaceutical composition comprising them; nucleic acids encoding the ligands, a vector comprising them, a host cell comprising the nucleic acids; a method of treating MSRV-associated diseases; an anti-ligand that is used to obtain an antibody; a method and a kit for detection of the anti-ligand in a sample, and also to the use of the kit.